Wie hoch ist der Preis für Hillstream BioPharma, Inc. (HILS)

Preis für Hillstream BioPharma, Inc. (HILS) ist $0.181

Wie hoch ist die Marktkapitalisierung für Hillstream BioPharma, Inc. (HILS)

Marktkapitalisierung für Hillstream BioPharma, Inc. (HILS) ist $2.03M

Hillstream BioPharma, Inc. (HILS) Kursverlauf

Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.

Jahr	Leistung
2023	-56.07%
2022	0.00%

Jahr

Leistung

2023

-56.07%

2022

0.00%

Unternehmen	Aktienkurs	Veränderung 1J%	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$505.24	28.63%	US
Argenx SE ARGX.US	$846.09	29.41%	NL
Lonza Group AG LONN.SW	$731.69	6.47%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$251.82	11.75%	BE

Unternehmen

Aktienkurs

Veränderung 1J%

Land